Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia
- PMID: 25641027
- PMCID: PMC4409832
- DOI: 10.1002/pd.4554
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia
Abstract
Introduction: Preeclampsia (PE) is a pregnancy-specific syndrome associated with adverse maternal and fetal outcomes. Patient-specific risks based on angiogenic factors might better categorize those who might have a severe adverse outcome.
Methods: Women evaluated for suspected PE at a tertiary hospital (2009-2012) had pregnancy outcomes categorized as 'referent' or 'severe', based solely on maternal/fetal findings. Outcomes that may have been influenced by a PE diagnosis were considered 'unclassified'. Soluble fms-like tyrosine kinase (sFlt1) and placental growth factor (PlGF) were subjected to bivariate discriminant modeling, allowing patient-specific risks to be assigned for severe outcomes.
Results: Three hundred twenty-eight singleton pregnancies presented at ≤34.0 weeks' gestation. sFlt1 and PlGF levels were adjusted for gestational age. Risks above 5 : 1 (10-fold over background) occurred in 77% of severe (95% CI 66 to 87%) and 0.7% of referent (95% CI <0.1 to 3.8%) outcomes. Positive likelihood ratios for the modeling and validation datasets were 19 (95% CI 6.2-58) and 15 (95% CI 5.8-40) fold, respectively.
Conclusions: This validated model assigns patient-specific risks of any severe outcome among women attending PE triage. In practice, women with high risks would receive close surveillance with the added potential for reducing unnecessary preterm deliveries among remaining women. © 2015 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
© 2015 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Figures





Similar articles
-
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29. Am J Obstet Gynecol. 2016. PMID: 26432463 Free PMC article.
-
Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia.PLoS One. 2015 May 12;10(5):e0126815. doi: 10.1371/journal.pone.0126815. eCollection 2015. PLoS One. 2015. PMID: 25965397 Free PMC article.
-
KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.Hypertens Pregnancy. 2016 Aug;35(3):330-45. doi: 10.3109/10641955.2016.1148162. Epub 2016 Mar 30. Hypertens Pregnancy. 2016. PMID: 27028795
-
Gestational angiogenic biomarker patterns in high risk preeclampsia groups.Am J Obstet Gynecol. 2013 Jul;209(1):53.e1-9. doi: 10.1016/j.ajog.2013.03.017. Epub 2013 Mar 18. Am J Obstet Gynecol. 2013. PMID: 23517919
-
Angiogenic factors for the prediction of preeclampsia in high-risk women.Am J Obstet Gynecol. 2007 Sep;197(3):244.e1-8. doi: 10.1016/j.ajog.2007.06.030. Am J Obstet Gynecol. 2007. PMID: 17826405 Clinical Trial.
Cited by
-
Prediction of adverse maternal and perinatal outcomes associated with pre-eclampsia and hypertensive disorders of pregnancy: a systematic review and meta-analysis.EClinicalMedicine. 2024 Sep 27;76:102861. doi: 10.1016/j.eclinm.2024.102861. eCollection 2024 Oct. EClinicalMedicine. 2024. PMID: 39391014 Free PMC article.
-
Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches.Front Physiol. 2018 Jul 25;9:973. doi: 10.3389/fphys.2018.00973. eCollection 2018. Front Physiol. 2018. PMID: 30090069 Free PMC article. Review.
-
Tracking placental development in health and disease.Nat Rev Endocrinol. 2020 Sep;16(9):479-494. doi: 10.1038/s41574-020-0372-6. Epub 2020 Jun 29. Nat Rev Endocrinol. 2020. PMID: 32601352 Review.
-
Effect of Low-Dose Aspirin on Soluble FMS-Like Tyrosine Kinase 1/Placental Growth Factor (sFlt-1/PlGF Ratio) in Pregnancies at High Risk for the Development of Preeclampsia.J Clin Med. 2019 Sep 10;8(9):1429. doi: 10.3390/jcm8091429. J Clin Med. 2019. PMID: 31510056 Free PMC article.
-
Circulating angiogenic factors in a pregnant woman on intensive hemodialysis: a case report.Can J Kidney Health Dis. 2016 Feb 23;3:7. doi: 10.1186/s40697-016-0096-7. eCollection 2016. Can J Kidney Health Dis. 2016. PMID: 26909159 Free PMC article.
References
-
- Organization WH. 2005. World Health Report. Make every mother and child count. Geneva.
-
- Friedman SA, Schiff E, Kao L, et al. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol. 1995;172:1785–8. discussion 1788–1792. - PubMed
-
- Thangaratinam S, Gallos ID, Meah N, et al. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2011;90:564–73. - PubMed
-
- Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG. 2006;113:369–78. - PubMed
-
- Thangaratinam S, Koopmans CM, Iyengar S, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scand. 2011;90:574–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous